Rapid helicobacter pylori detection reagent and method based on RPA-CRISPR-Cas12a combined with digital microfluidic platform
Through the digital microfluidic control platform combined with RPA-CRISPR-Cas12a, the problems of rapid, accurate and safe in Helicobacter pylori detection are solved, and the high sensitivity and specific detection of Helicobacter pylori are achieved, which is suitable for rapid detection in multiple occasions. application.
Patent Information
- Application Number
- CN202411258747.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-22
AI Technical Summary
The existing Helicobacter pylori detection methods cannot achieve fast, simple and accurate genetic diagnosis and virulence classification, and conventional methods have problems such as high sensitivity but high equipment requirements, complex operation, and aerosol contamination.
Using a digital microfluidic platform based on RPA-CRISPR-Cas12a binding, Helicobacter pylori-related genes were screened through specific primers and crRNA, combining automated drop control and oil phase media to achieve high sensitivity and specific multiple detection.
It realizes early diagnosis and precise classification of Helicobacter pylori, reduces operating steps and costs, reduces the risk of aerosol contamination, and is suitable for rapid testing in hospitals and out-of-hospital occasions.
Smart Images

Figure CN118995974A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical molecular diagnostic technology, and in particular to a Helicobacter pylori rapid detection reagent and method based on RPA-CRISPR-Cas12a combined with a digital microfluidics platform. Background Art
[0002] Helicobacter pylori (Hp) is a spiral-shaped, slightly anaerobic, Gram-negative bacillus with a strong ability to survive in the highly acidic environment of the stomach. This bacterium is closely associated with diseases such as gastritis and gastric ulcers and is classified as a Class I carcinogen by the World Health Organization. Epidemiological data show that approximately half of the world's population is infected with H. pylori. The pathogenicity of H. pylori is associated with its virulence factors, particularly the cytotoxin-associated protein A (CagA) and vacuolation cytotoxin (VacA) genes. These virulence factors play a key role in the clinical outcome of infection. Based on the expression of these two genes, H. pylori infection can be classified into the more virulent type I and the less virulent type II. The prevalence of gastric cancer and ulcers in type I infection is significantly higher than in type II infection. Therefore, eradication therapy is necessary for type I infection, while symptomatic treatment can be used for type II infection based on specific circumstances.
[0003] Currently, there are a wide variety of methods for detecting H. pylori, but each method comes with its own specific limitations. First, many conventional detection methods, such as the urea breath test and immunological methods, can effectively identify H. pylori infection, but they cannot further enable H. pylori typing. Methods that can achieve typing, such as real-time fluorescence quantitative polymerase chain reaction (qPCR) and stool antigen testing, can theoretically distinguish different types of H. pylori, but these methods also have limitations. For example, rapid urease tests and qPCR tests are highly sensitive and produce accurate and reliable results, but they have relatively high requirements for testing equipment, laboratory environment, and operators. While stool antigen testing can type, its results may be affected by the patient's diet, medication intake, and other intestinal microorganisms, thus affecting its accuracy. Therefore, the current diagnosis of H. pylori infection still lacks a simple, convenient, accurate, and rapid "point-of-care" method that can simultaneously detect H. pylori and type its virulence.
[0004] Clustered regularly interspaced short palindromic repeats and associated proteins (CRISPR-Cas) are an immune defense mechanism present in most bacteria and archaea. This mechanism forms the CRISPR / Cas system with nucleic acid cleavage capabilities through the synergistic action of CRISPR and Cas proteins (CRISPR-associated protein, Cas). In recent years, this system has shown great potential in the field of nucleic acid detection. However, this method also has some limitations. For example, the combination of constant temperature amplification and the CRISPR / Cas system may make the operation steps more complicated and involve higher costs. In addition, opening the lid after amplification is prone to aerosol contamination, resulting in false positive results. Complex manual operations further increase this risk.
[0005] Digital microfluidics (DMF) is an emerging, full-range droplet manipulation technology based on the principle of dielectric wetting, enabling automated control of discrete droplets. It can perform basic operations such as transport, generation, merging, and splitting of droplets at the picoliter scale and above, integrating complex laboratory analytical processing onto a single DMF chip, hence the term "lab on a chip." Its advantages lie in its low cost, simple fabrication, high degree of integration, and programmable control, demonstrating promising application potential in molecular diagnostics. It is particularly well-suited to addressing the aforementioned challenges of combining constant-temperature amplification with CRISPR / Cas systems, effectively meeting the requirements of rapid testing and portable operation, making it suitable for a variety of settings both in hospitals and beyond.
[0006] Large-scale H. pylori virulence typing testing in the population can provide important experimental diagnostic evidence for the implementation of selective eradication therapy in the clinic. Therefore, there is an urgent need for a rapid detection method that can achieve rapid genetic diagnosis and virulence typing of H. pylori. Summary of the Invention
[0007] The purpose of the present invention is to provide a rapid multiplex detection of three target nucleic acid molecules of Helicobacter pylori using a digital microfluidic platform with high sensitivity and high specificity. This multiplex detection can effectively avoid aerosol contamination and is very suitable for Helicobacter pylori rapid detection reagents and methods based on RPA-CRISPR-Cas12a combined with a digital microfluidic platform in various occasions in and outside hospitals.
[0008] The Helicobacter pylori rapid detection reagent of the present invention includes a primer pair for detecting the CagA gene, a primer pair for detecting the VacA gene, and a primer pair for detecting the ureB gene, specific crRNA for detecting the Helicobacter pylori cagA gene, vacA gene, and ureB gene, an ssDNA fluorescent reporter for a method for rapid detection and virulence typing of Helicobacter pylori, a recombinase polymerase amplification RPA reaction reagent for detecting the cagA gene, a recombinase polymerase amplification RPA reaction reagent for detecting the vacA gene, a recombinase polymerase amplification RPA reaction reagent for detecting the ureB gene, a CRISPR-Cas12a reaction reagent for detecting the cagA gene, a CRISPR-Cas12a reaction reagent for detecting the vacA gene, a CRISPR-Cas12a reaction reagent for detecting the ureB gene, and a digital microfluidics platform;
[0009] The primer pair for detecting the CagA gene is a cagA upstream primer and a cagA downstream primer;
[0010] The cagA upstream primer is TAACAACCCTAGTTTTTATCTCTACAAAGAAG, and the cagA downstream primer is GCTTAGAGTCTTTTTGAAAATCCTTAATCTCA;
[0011] The primer pairs for detecting the VacA gene are respectively a VacA upstream primer and a VacA downstream primer;
[0012] The VacA upstream primer is CTTTTAGTGGAAAATCTAACCGGGAATATCAC, and the VacA downstream primer is AAATCTTCCCAGACTAATATCGTTATTGAAAG;
[0013] The primer pair for detecting the ureB gene is a ureB upstream primer and a ureB downstream primer;
[0014] The ureB upstream primer is GCTGAAGAATATTCTATGAACTTAGGTTTCTT, and the ureB downstream primer is CTTGCACATCGTATTTGTCTGCAACATCTAAC;
[0015] The specific cagA-crRNA for detecting the cagA gene, i.e., the cagA-crRNA is UAAUUUCUAAGUGUAGAUGGATCTCTTCTTGACTCAAT or UAAUUUCUACUAAGUGUAGAUTGCAAGAAATTCCATGAAAT;
[0016] The specific vacA-crRNA for detecting the vacA gene, i.e., the vacA-crRNA is UAAUUUCUAAGUGUAGAUGCAGGATCAAGCGCGAATTT or UAAUUUCUAAGUGUAGAUGTATCCACACCAGCCTTAAA;
[0017] The specific ureB-crRNA for detecting the ureB gene, that is, the ureB-crRNA is UAAUUUCUAAGUGUAGAUATCCGCTAAGCTCGCGTCGT or UAAUUUCUACUAAGUGUAGAUAAGCCAATCGCACCGGCTTC;
[0018] The structure of the ssDNA fluorescent reporter for the method for rapid detection and virulence typing of Helicobacter pylori is FAM-8N-TAMRA, specifically 5′-FAM-TTATTATT-TAMRA-3′;
[0019] The RPA reaction reagent for detecting the cagA gene includes: 37 μL of RPA reaction buffer, 1.5 μL of deoxyribonucleoside triphosphate mixture, the initial concentration of the deoxyribonucleoside triphosphate mixture is 10 mM, 2 μL of cagA upstream primer, the initial concentration of the cagA upstream primer is 10 μM, 2 μL of cagA downstream primer, the initial concentration of the cagA downstream primer is 10 μM, 2 μL of sample DNA, 3 μL of DEPC-treated water, and 2.5 μL of magnesium acetate, the initial concentration of magnesium acetate is 280 mM.
[0020] The RPA reaction reagent for detecting the vacA gene includes: 37 μL of RPA reaction buffer, 1.5 μL of deoxyribonucleoside triphosphate mixture, the initial concentration of the deoxyribonucleoside triphosphate is 10 mM, 2 μL of vacA upstream primer, the initial concentration of the vacA upstream primer is 10 μM, 2 μL of vacA downstream primer, the initial concentration of the vacA downstream primer is 10 μM, 2 μL of sample DNA, 3 μL of DEPC-treated water, and 2.5 μL of magnesium acetate, the initial concentration of magnesium acetate is 280 mM.
[0021] The RPA reaction reagent for detecting the ureB gene includes: 37 μL of RPA reaction buffer, 1.5 μL of deoxyribonucleoside triphosphate mixture, the initial concentration of deoxyribonucleoside triphosphate is 10 mM, 2 μL of ureB upstream primer, the initial concentration of ureB upstream primer is 10 μM, 2 μL of ureB downstream primer, the initial concentration of ureB downstream primer is 10 μM, 2 μL of sample DNA, 3 μL of DEPC-treated water, and 2.5 μL of magnesium acetate solution, the initial concentration of magnesium acetate is 280 mM.
[0022] The CRISPR-Cas12a reaction reagent for detecting the cagA gene includes 2 μL of RPA amplification product, 1.25 μL of cagA-crRNA, the starting concentration of cagA-crRNA is 1 μM, 2 μL of NEBuffer r2.1, 1 μL of LbCas12a protein, the starting concentration of LbCas12a protein is 1 μM, 1 μL of ssDNA fluorescent reporter, the starting concentration of ssDNA fluorescent reporter is 10 mM, and 12.75 μL of DEPC water;
[0023] The CRISPR-Cas12a reaction reagent for detecting the vacA gene includes 2 μL of RPA amplification product, 1.25 μL of vacA-crRNA, the starting concentration of vacA-crRNA is 1 μM, 2 μL of NEBuffer r2.1, 1 μL of LbCas12a protein, the starting concentration of LbCas12a protein is 1 μM, 1 μL of ssDNA fluorescent reporter, the starting concentration of ssDNA fluorescent reporter is 10 mM), and 12.75 μL of DEPC water;
[0024] The CRISPR-Cas12a reaction reagent for detecting the ureB gene includes 2 μL of RPA amplification product, 1.25 μL of ureB-crRNA, the starting concentration of ureB-crRNA is 1 μM, 2 μL of NEBuffer r2.1, 1 μL of LbCas12a protein, the starting concentration of LbCas12a protein is 1 μM, 1 μL of ssDNA fluorescent reporter, the starting concentration of ssDNA fluorescent reporter is 10 mM, and 12.75 μL of DEPC water;
[0025] The right side of the digital microfluidic platform is provided with a sample loading area, a cagA-RPA reagent area, a vacA-RPA reagent area, and a ureB-RPA reagent area; the cagA-RPA reagent area is pre-stored with a recombinase polymerase amplification RPA reaction reagent for detecting the cagA gene, the vacA-RPA reagent area is pre-stored with a recombinase polymerase amplification RPA reaction reagent for detecting the vacA gene, and the ureB-RPA reagent area is pre-stored with a recombinase polymerase amplification RPA reaction reagent for detecting the ureB gene;
[0026] The left side of the digital microfluidic platform is provided with a negative control loading area, a cagA-CRISPR reagent area, a vacA-CRISPR reagent area and a ureB-CRISPR reagent area; the cagA-CRISPR reagent area is pre-stored with a CRISPR-Cas12a reaction reagent for detecting the cagA gene, the vacA-CRISPR reagent area is pre-stored with a CRISPR-Cas12a reaction reagent for detecting the vacA gene, and the ureB-CRISPR reagent area is pre-stored with a CRISPR-Cas12a reaction reagent for detecting the ureB gene.
[0027] Preferably, the bottom of the digital microfluidic platform is provided with an indium tin oxide glass bottom plate, and the top of the digital microfluidic platform is provided with an indium tin oxide glass top plate, and the right side of the indium tin oxide glass top plate is respectively provided with RPA reagent injection holes for adding recombinase polymerase amplification RPA reaction reagents for detecting cagA gene, recombinase polymerase amplification RPA reaction reagents for detecting vacA gene, and recombinase polymerase amplification RPA reaction reagents for detecting ureB gene, and the right side of the indium tin oxide glass top plate is also provided with a sample injection hole for adding samples; the left side of the object glass top plate is respectively provided with CRISPR-Cas12a reagent injection holes for adding CRISPR-Cas12a reaction reagents for detecting cagA gene, CRISPR-Cas12a reaction reagents for detecting vacA gene, and CRISPR-Cas12a reaction reagents for detecting ureB gene.
[0028] A method for detecting Helicobacter pylori using the Helicobacter pylori rapid detection reagent of the present invention comprises the following steps:
[0029] A. Prepare a digital microfluidic platform as described above;
[0030] B. Add the nucleic acid sample to be tested to the sample loading area on the right side of the digital microfluidic platform;
[0031] C. The detection results can be determined by monitoring the changes in the fluorescence signal through the digital microfluidic platform.
[0032] The Helicobacter pylori rapid detection reagent based on RPA-CRISPR-Cas12a combined with a digital microfluidic platform of the present invention has the following advantages over the prior art:
[0033] 1. The present invention provides a highly automated method for detecting Helicobacter pylori using a rapid Helicobacter pylori detection reagent. Using specific RPA primers and crRNA, it effectively screens for genes associated with H. pylori hypervirulence, such as cagA, vacA, and ureB. This design significantly improves the sensitivity and specificity of detection, allowing for early diagnosis and accurate typing of H. pylori infection and its virulence.
[0034] 2. The present invention integrates isothermal amplification with CRISPR / Cas12a, uses programmed automated droplet control and a closed environment provided by an oil-phase medium, effectively reducing the number of operation steps and time, significantly reducing the amount of reagents and experimental costs, and reducing the risk of aerosol contamination.
[0035] 3. The DMF nucleic acid detection system established by the present invention is compact, highly integrated, and highly portable, making it suitable not only for laboratory environments but also for rapid on-site testing. It can be integrated with various detection devices, such as temperature control units and fluorescence detection modules, making the platform suitable not only for resource-limited environments but also for meeting clinical needs for high sensitivity and specificity. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 This is a schematic diagram of the detection reaction process of the digital microfluidic platform of the present invention in the sample distribution stage;
[0037] Figure 2 This is a schematic diagram of the three recombinase polymerase amplification (RPA) reaction reagents in the distribution and mixing stages in the detection reaction process of the digital microfluidic platform of the present invention;
[0038] Figure 3 This is a schematic diagram of the three CRISPR-Cas12a reaction reagents in the detection reaction process of the digital microfluidic platform of the present invention in the distribution and mixing stage;
[0039] Figure 4 This is a schematic diagram of the result reading stage in the detection reaction process of the digital microfluidic platform of the present invention; DETAILED DESCRIPTION
[0040] The embodiments of the present invention are described in detail below. The embodiments are implemented based on the technical solutions of the present invention, and detailed implementation methods and specific operating processes are given. However, the protection scope of the present invention is not limited to the following embodiments.
[0041] The present invention provides a method for detecting Helicobacter pylori using the Helicobacter pylori rapid detection reagent of the present invention, that is, a method for rapid detection and virulence typing of Hp based on RPA-CRISPR-Cas12a combined with a DMF system, specifically comprising: first extracting sample DNA, performing RPA isothermal amplification on the extracted sample DNA, and obtaining an amplified product, adding the amplified product to the CRISPR-Cas12a system, and performing ultra-sensitive specific recognition of crRNA and the amplified product dsDNA under the action of the Cas12a enzyme, thereby activating the trans-cleavage function to cut the ssDNA fluorescent reporter, integrating the above detection process into a DMF chip, and automatically controlling the movement and reaction of droplets on the chip by the DMF operating system software, including sample distribution, RPA reagent mixing, CRISPR reagent mixing, and final fluorescence signal reading or directly observing the color change by ultraviolet light to judge the detection result.
[0042] Determination of detection targets
[0043] First, by collecting the sequences of Helicobacter pylori Hp genes from the NCBI GenBank database, multiple sequence alignment was performed using the ClustalOmega tool to identify highly conserved sequence regions between various Hp strains. Further, specificity analysis was performed using the BLAST tool to ensure that the selected sequences had no significant similarity in other species, thereby determining the detection target sequences of the cagA gene, vacA gene, and ureB gene. The basis for selecting these target sequences is their high conservation in Helicobacter pylori Hp and their association with the high virulence phenotype. The specific detection target sequences are cagA detection target sequence cagA target as shown in SEQ ID No.14, vacA detection target sequence vacAtarget as shown in SEQ ID No.15, and ureB detection target sequence ureB target as shown in SEQ ID No.16. In this example, extraction and purification of positive clone plasmids were also performed, and the correctness of the inserted gene sequence was verified by Sanger sequencing.
[0044] Table 1 Target sequences for cagA, vacA and ureB gene detection
[0045]
[0046]
[0047] The Helicobacter pylori rapid detection reagent of the present invention includes a primer pair for detecting a cytotoxin-associated protein A gene, also known as the CagA gene, a primer pair for detecting a vacuolar cytotoxin gene, also known as the VacA gene, and a primer pair for detecting a urease B gene, also known as the ureB gene, specific crRNA for detecting the Helicobacter pylori cagA gene, vacA gene, and ureB gene, an ssDNA fluorescent reporter for a method for rapid detection and virulence typing of Helicobacter pylori, a recombinase polymerase amplification RPA reaction reagent for detecting the cagA gene, a recombinase polymerase amplification RPA reaction reagent for detecting the vacA gene, a recombinase polymerase amplification RPA reaction reagent for detecting the ureB gene, a CRISPR-Cas12a reaction reagent for detecting the cagA gene, a CRISPR-Cas12a reaction reagent for detecting the vacA gene, a CRISPR-Cas12a reaction reagent for detecting the ureB gene, and a digital microfluidics platform;
[0048] Based on the CagA gene of Helicobacter pylori Hp, using IDT PrimerQuest TM RPA primers were designed based on the detection target sequence of the online tool to obtain a primer pair for detecting the CagA gene. The primer pair for detecting the CagA gene was a cagA upstream primer and a cagA downstream primer. The RPA primer sequence of the cagA upstream primer was numbered as SEQ ID No. 1 in Table 2 below, and the RPA primer sequence of the cagA downstream primer was numbered as SEQ ID No. 2 in Table 2 below.
[0049] The cagA upstream primer is TAACAACCCTAGTTTTTATCTCTACAAAGAAG, and the cagA downstream primer is GCTTAGAGTCTTTTTGAAAATCCTTAATCTCA;
[0050] Based on the VacA gene of Helicobacter pylori Hp, using IDT PrimerQuest TM RPA primers were designed based on the detection target sequence of the online tool to obtain a primer pair for detecting the VacA gene. The primer pair for detecting the VacA gene was a VacA upstream primer and a VacA downstream primer. The RPA primer sequence of the VacA upstream primer was numbered as SEQ ID No. 3 in Table 2 below, and the RPA primer sequence of the VacA downstream primer was numbered as SEQ ID No. 4 in Table 2 below.
[0051] The VacA upstream primer is CTTTTAGTGGAAAATCTAACCGGGAATATCAC, and the VacA downstream primer is AAATCTTCCCAGACTAATATCGTTATTGAAAG;
[0052] Based on the ureB gene of Helicobacter pylori Hp, using IDT PrimerQuest TM RPA primers were designed based on the detection target sequence of the online tool to obtain a primer pair for detecting the ureB gene. The primer pair for detecting the ureB gene was a ureB upstream primer and a ureB downstream primer. The RPA primer sequence of the ureB upstream primer was numbered as SEQ ID No. 5 in Table 2 below, and the RPA primer sequence of the ureB downstream primer was numbered as SEQ ID No. 6 in Table 2 below.
[0053] The ureB upstream primer is GCTGAAGAATATTCTATGAACTTAGGTTTCTT, and the ureB downstream primer is CTTGCACATCGTATTTGTCTGCAACATCTAAC;
[0054] Table 2
[0055]
[0056] The above primers were designed using IDT PrimerQuest TM The online tool designs RPA primers based on the target sequences of the H. pylori cagA, vacA, and ureB genes. Primer design considerations include oligonucleotide chain length, GC content, Tm value, and avoiding primer self-amplification and dimer formation. To ensure primer specificity, the amplified product length is typically between 100-200 bp, and the primer length is 30-35 bp. The RPA primer sequences for detecting the cagA gene are as shown in SEQ ID Nos. 1 and 2 for the cagA primer pair; the RPA primer sequences for detecting the vacA gene are as shown in SEQ ID Nos. 3 and 4 for the vacA primer pair; and the RPA primer sequences for detecting the ureB gene are as shown in SEQ ID Nos. 5 and 6 for the ureB primer pair. The amplified fragments obtained using these primer pairs are 105 bp in length for cagA, 198 bp for vacA, and 158 bp for ureB, respectively.
[0057] Based on the CagA gene of Helicobacter pylori Hp, the specific crRNA design adopts the "Casilico" software package in R language for designing and screening crRNA design principles that meet Cas12a to design the crRNA of the CRISPR-Cas12a system, ensuring that PAM (TTTN) is located at the 3' end of the target sequence, the specific crRNA length includes a 20nt pre-spacer sequence and a structural sequence, and the GC content is controlled at 40-60%. The specific crRNA is ensured by BLAST;
[0058] The specific cagA-crRNA for detecting the cagA gene has a sequence number of SEQ ID No. 7 or SEQ ID No. 8 in Table 3 below, that is, the cagA-crRNA is:
[0059] UAAUUUCUACUAAGUGUAGAUGGATCTCTTCTTGACTCAAT or UAAUUUCUACUAAGUGUAGAUTGCAAGAAATTCCATGAAAT;
[0060] The specific vacA-crRNA for detecting the vacA gene has a sequence number of SEQ ID No. 9 or SEQ ID No. 10 in Table 3 below, that is, the vacA-crRNA is:
[0061] UAAUUUCUACUAAGUGUAGAUGCAGGATCAAGCGCGAATTT or UAAUUUCUACUAAGUGUAGAUGTATCCACACCAGCCTTAAA;
[0062] The specific ureB-crRNA for detecting the ureB gene has a sequence number of SEQ ID No. 11 or SEQ ID No. 12 in Table 3 below, i.e., the ureB-crRNA is:
[0063] UAAUUUCUACUAAGUGUAGAUATCCGCTAAGCTCGCGTCGT or UAAUUUCUACUAAGUGUAGAUAAGCCAATCGCACCGGCTTC;
[0064] Table 3
[0065]
[0066] The above three crRNA designs are designed using the "Casilico" software package in R language for designing and screening crRNA design principles that meet Cas12a to design the crRNA of the CRISPR-Cas12a system, ensuring that PAM (TTTN) is located at the 3' end of the target sequence. Various crRNA lengths include 20nt pre-spacer sequences and structural sequences, and the GC content is controlled at 40-60%, and specificity is ensured by BLAST. The two candidate specific crRNA sequences for detecting cagA genes are cagA-crRNA such as shown in SEQ ID No.7 to 8; the two candidate specific crRNA sequences for detecting vagA genes are vagA-crRNA such as shown in SEQ ID No.9 and 10; the two candidate specific crRNA sequences for detecting vagA genes are ureB-crRNA such as shown in SEQ ID No.11 and 12. It should be noted that the technical solution of selecting any one sequence in SEQ ID No.7 to 12 as crRNA is within the scope of protection of the present invention.
[0067] The structure of the ssDNA fluorescent reporter for the method for rapid detection and virulence typing of Helicobacter pylori is FAM-8N-TAMRA, specifically 5′-FAM-TTATTATT-TAMRA-3′;
[0068] The RPA reaction reagent for detecting the cagA gene includes: 37 μL of RPA reaction buffer, 1.5 μL of deoxyribonucleoside triphosphate mixture, the initial concentration of the deoxyribonucleoside triphosphate mixture is 10 mM, 2 μL of cagA upstream primer, the initial concentration of the cagA upstream primer is 10 μM, 2 μL of cagA downstream primer, the initial concentration of the cagA downstream primer is 10 μM, 2 μL of sample DNA, 3 μL of DEPC-treated water, and 2.5 μL of magnesium acetate, the initial concentration of magnesium acetate is 280 mM.
[0069] The RPA reaction reagent for detecting the vacA gene includes: 37 μL of RPA reaction buffer, 1.5 μL of deoxyribonucleoside triphosphate mixture, the initial concentration of the deoxyribonucleoside triphosphate is 10 mM, 2 μL of vacA upstream primer, the initial concentration of the vacA upstream primer is 10 μM, 2 μL of vacA downstream primer, the initial concentration of the vacA downstream primer is 10 μM, 2 μL of sample DNA, 3 μL of DEPC-treated water, and 2.5 μL of magnesium acetate, the initial concentration of magnesium acetate is 280 mM.
[0070] The RPA reaction reagent for detecting the ureB gene includes: 37 μL of RPA reaction buffer, 1.5 μL of deoxyribonucleoside triphosphate mixture, the initial concentration of deoxyribonucleoside triphosphate is 10 mM, 2 μL of ureB upstream primer, the initial concentration of ureB upstream primer is 10 μM, 2 μL of ureB downstream primer, the initial concentration of ureB downstream primer is 10 μM, 2 μL of sample DNA, 3 μL of DEPC-treated water, and 2.5 μL of magnesium acetate solution, the initial concentration of magnesium acetate is 280 mM.
[0071] The RPA reaction buffer was from the recombinase polymerase amplification kit (WLB5001) of Weifang Anpu Future Biotechnology Co., Ltd.
[0072] The CRISPR-Cas12a reaction reagent for detecting the cagA gene includes 2 μL of RPA amplification product, 1.25 μL of cagA-crRNA, the starting concentration of cagA-crRNA is 1 μM, 2 μL of NEBuffer r2.1, 1 μL of LbCas12a protein, the starting concentration of LbCas12a protein is 1 μM, 1 μL of ssDNA fluorescent reporter, the starting concentration of ssDNA fluorescent reporter is 10 mM, and 12.75 μL of DEPC water;
[0073] The CRISPR-Cas12a reaction reagent for detecting the vacA gene includes 2 μL of RPA amplification product, 1.25 μL of vacA-crRNA, the starting concentration of vacA-crRNA is 1 μM, 2 μL of NEBuffer r2.1, 1 μL of LbCas12a protein, the starting concentration of LbCas12a protein is 1 μM, 1 μL of ssDNA fluorescent reporter, the starting concentration of ssDNA fluorescent reporter is 10 mM), and 12.75 μL of DEPC water;
[0074] The CRISPR-Cas12a reaction reagent for detecting the ureB gene includes 2 μL of RPA amplification product, 1.25 μL of ureB-crRNA, the starting concentration of ureB-crRNA is 1 μM, 2 μL of NEBuffer r2.1, 1 μL of LbCas12a protein, the starting concentration of LbCas12a protein is 1 μM, 1 μL of ssDNA fluorescent reporter, the starting concentration of ssDNA fluorescent reporter is 10 mM, and 12.75 μL of DEPC water;
[0075] See also Figure 1 、 Figure 2 Figure 3 and Figure 4The right side of the digital microfluidic platform is provided with a sample loading area 1, a cagA-RPA reagent area 2, a vacA-RPA reagent area 3 and a ureB-RPA reagent area 4; the cagA-RPA reagent area 2 is pre-stored with a recombinase polymerase amplification RPA reaction reagent for detecting the cagA gene, the vacA-RPA reagent area 3 is pre-stored with a recombinase polymerase amplification RPA reaction reagent for detecting the vacA gene, and the ureB-RPA reagent area 4 is pre-stored with a recombinase polymerase amplification RPA reaction reagent for detecting the ureB gene;
[0076] A negative control loading area 5, a cagA-CRISPR reagent area 6, a vacA-CRISPR reagent area 7 and a ureB-CRISPR reagent area 8 are provided on the left side of the digital microfluidic platform; the CRISPR-Cas12a reaction reagent for detecting the cagA gene is pre-stored in the cagA-CRISPR reagent area 6, the CRISPR-Cas12a reaction reagent for detecting the vacA gene is pre-stored in the vacA-CRISPR reagent area 7, and the CRISPR-Cas12a reaction reagent for detecting the ureB gene is pre-stored in the ureB-CRISPR reagent area 8.
[0077] As a further improvement of the present invention, the bottom of the above-mentioned digital microfluidic platform is provided with an indium tin oxide glass bottom plate, and the top of the digital microfluidic platform is provided with an indium tin oxide glass top plate. The right side of the indium tin oxide glass top plate is respectively provided with RPA reagent injection holes for adding recombinase polymerase amplification RPA reaction reagents for detecting the cagA gene, the recombinase polymerase amplification RPA reaction reagents for detecting the vacA gene, and the recombinase polymerase amplification RPA reaction reagents for detecting the ureB gene. The right side of the indium tin oxide glass top plate is also provided with a sample injection hole for adding samples; the left side of the object glass top plate is respectively provided with CRISPR-Cas12a reagent injection holes for adding CRISPR-Cas12a reaction reagents for detecting the cagA gene, the CRISPR-Cas12a reaction reagents for detecting the vacA gene, and the CRISPR-Cas12a reaction reagents for detecting the ureB gene.
[0078] A method for detecting Helicobacter pylori using the above-mentioned Helicobacter pylori rapid detection reagent of the present invention comprises the following steps:
[0079] A. Prepare a digital microfluidic platform of the present invention;
[0080] B. Add the nucleic acid sample to be tested to the sample loading area 1 on the right side of the digital microfluidic platform;
[0081] C. The detection results can be determined by monitoring the changes in the fluorescence signal through the digital microfluidic platform.
[0082] Unless otherwise specified, the reagents or equipment used in the present invention are all conventional reagents in this technical field, and the materials are all commercially available.
[0083] The digital microfluidics platform used in this invention, also known as the DMF platform, includes a DMF chip with a high-precision electrode manipulation system. Leveraging advanced microcontroller technology and programmed control, this DMF chip dynamically manages the precise movement and manipulation of droplets, supporting the demands of complex chemical and biological experiments. The DMF chip utilizes a multilayer structure, from bottom to top, comprising an ITO glass baseplate, an ITO electrode layer, a Si3N4 dielectric layer, and a hydrophobic layer.
[0084] The DMF platform also features a temperature control module and a fluorescence detection module to support a wide range of biochemical reactions. The temperature control module uses Peltier elements for rapid heating and precise temperature control, while the fluorescence detection module includes a light source, excitation filters, detection filters, and a photomultiplier tube to ensure highly sensitive signal detection.
[0085] The temperature control module in the DMF system is responsible for maintaining the optimal temperature (37°C) of all reaction zones on the chip to ensure the consistency of reaction conditions and the reliability of the results. Before loading the DMF chip, ensure that the chip surface is clean and undamaged. After the chip is loaded, accurately connect the data line and power supply through the interface of the DMF system, and use the system software to set and calibrate the position and direction of the chip to ensure the precise movement of the droplets. Slowly add about 1400μL of silicone oil to the chip oil filling port to fill the interlayer gap inside the chip to provide a stable medium environment for the movement of droplets while preventing chemical contamination.
[0086] The digital microfluidic platform can control the precise movement of droplets through the preset DMF operating system software. The system automatically controls the switching of electrodes according to the programmed path to achieve the positioning, movement, distribution, merging and splitting of droplets.
[0087] During the droplet manipulation phase of the digital microfluidics platform, its control system first automatically distributes samples and negative controls to the corresponding reaction zones according to the designed path. The system then automatically guides the RPA and CRISPR reagents to their respective reaction zones, ensuring sufficient mixing and reaction of the droplets. The specific process includes: samples and negative controls are distributed from the loading zone to the reaction zone according to the preset path; the RPA reagent is mixed with the sample in the reaction zone and then allowed to stand to complete the amplification reaction; the CRISPR reagents are then introduced one by one into the corresponding reaction zone and mixed with the amplified products to complete the CRISPR-Cas12a reaction. After the reaction is complete, the fluorescent signal is read at a specific wavelength using the chip's built-in high-sensitivity fluorescence detection module.
[0088] The detection process on the DMF chip of the present invention is as follows Figure 1 、 Figure 2 、 Figure 3 and Figure 4 As shown, Figure 1 This is a schematic diagram of the detection reaction process of the digital microfluidic platform of the present invention at the sample distribution stage for 2 minutes. Figure 2 This is a schematic diagram of the three recombinase polymerase amplification (RPA) reaction reagents in the detection reaction process of the digital microfluidic platform of the present invention in the distribution and mixing stage for 18 minutes. Figure 3 This is a schematic diagram of the three CRISPR-Cas12a reaction reagents in the detection reaction process of the digital microfluidic platform of the present invention when they are in the distribution and mixing stage for 10 minutes. Figure 4 This is a schematic diagram of the digital microfluidic platform of the present invention at the 30-minute result reading stage of the detection reaction process. In addition, the reaction result can also be determined by directly observing the color change of the DMF chip reaction area under ultraviolet light.
[0089] On the DMF platform, the integrated fluorescence detection module monitors fluorescence signals in real time throughout the entire detection process. From the start of the experiment to 30 minutes, the system records the normalized fluorescence intensity of the cagA, vacA, and ureB target genes. Experimental data demonstrate that even at a minimum reaction concentration of 10 copies, the detection sensitivity of all three genes reached significant levels (P<0.0001), with clear fluorescence signal differentiation compared to the negative control.
[0090] Experiments showed that the signals of the three target genes, cagA, vacA, and ureB, continued to increase over time, reaching a peak within 35 minutes. Samples with high gene copy numbers exhibited stronger fluorescence signals and reached their peak more quickly. Furthermore, testing across the entire concentration range demonstrated high detection consistency and reliability, confirming that the assay can accurately detect even at extremely low template concentrations.
[0091] DEPC-treated water was used as a negative control to ensure the control conditions of the experiment. The experiment was repeated three times for each concentration of template solution to enhance the reliability and repeatability of the results.
[0092] The three target gene sequence templates of cagA, vacA and ureB were diluted to 10 5 copies / μL. Cross-validation was performed using these templates, immobilizing one target DNA and replacing the crRNA with a different target gene. DEPC-treated water was used as a negative control. This setup was designed to evaluate the detection system's ability to recognize specific targets. Each experiment was repeated three times to enhance data reliability.
[0093] The droplet operation procedure on the DMF system of the present invention mixes the reagents with each diluted target gene sample in a designated area for reaction. During the entire chip detection process, the integrated fluorescence detection module performs real-time in-situ fluorescence signal monitoring.
[0094] The specificity test results showed that in 10 5 At a concentration of 100 copies / μL, the DMF system using specific crRNA accurately identified and matched the target gene sequence templates for cagA, vacA, and ureB. Fluorescence monitoring results confirmed that the method could clearly and accurately distinguish these three H. pylori genes, demonstrating the good specificity of the detection method.
[0095] Preliminary clinical sample validation
[0096] Saliva and stool samples were collected from clinical patients according to strict selection and exclusion criteria. All samples were collected under ethically acceptable conditions, and nucleic acid was extracted and purified using standardized procedures. Nucleic acid extraction was performed for both saliva and stool samples. DNA was extracted from saliva using the Universal Genomic DNA Extraction Kit (PD705) using a magnetic bead method; DNA was extracted from stool using the Fecal Genomic DNA Extraction Kit (PD328).
[0097] 80 saliva samples and 55 stool samples were analyzed using the carbon-13 urea breath test ( 13 C-UBT) and qPCR were used as comparison methods to evaluate the diagnostic sensitivity and specificity of the RPA-CRISPR / DMF method. 13 Comparative validation of C-UBT and qPCR, and calculation of κ values.
[0098] 1) Saliva sample test results: In the analysis of 80 saliva samples, the method of detecting Helicobacter pylori using the Helicobacter pylori rapid detection reagent of the present invention, that is, the RPA-CRISPR / DMF method, can accurately identify all Helicobacter pylori. 13 C-UBT confirmed positive samples and demonstrated a diagnostic specificity of 93% in negative samples (see Table 4 ), with a κ value of 0.88.
[0099] In addition, comparison with the results of qPCR also showed 100% diagnostic sensitivity and specificity (see Table 5 ), with a κ value of 1.0.
[0100] Table 4 Clinical saliva sample RPA-CRISPR / DMF and 13 C-UBT result comparison
[0101]
[0102] Table 5 Comparison of RPA-CRISPR / DMF and qPCR results of clinical saliva samples
[0103]
[0104] 2) Stool Sample Detection Results: In the analysis of 55 stool samples, the present invention's method for detecting H. pylori using the H. pylori rapid detection reagent, namely the RPA-CRISPR / DMF method, demonstrated 79% diagnostic sensitivity and 100% diagnostic specificity (see Table 6), with a κ value of 0.75. Comparison of this method with qPCR results also demonstrated 100% diagnostic sensitivity and specificity (see Table 7), with a κ value of 1.0, indicating perfect consistency in stool sample detection.
[0105] Table 6 Clinical stool sample RPA-CRISPR / DMF and 13 C-UBT result comparison
[0106]
[0107] Table 7 Comparison of RPA-CRISPR / DMF and qPCR results of clinical stool samples
[0108]
[0109]
[0110] The above-described embodiments are merely preferred embodiments of the present invention and should not limit the scope of protection of the present invention. Protection of the present invention should be based on the claims and the description and include all technical solutions within the concept and spirit of the present invention. Any non-substantial changes in form or detail that do not change the basic function or working mode of the present invention shall fall within the scope of protection of the patent claims of the present invention. Any content not fully described in the present invention is conventional technical content.
Claims
1. A Helicobacter pylori rapid detection reagent, characterized in that: Including primer pairs for detecting CagA genes, primer pairs for detecting VacA genes and primer pairs for detecting ureB genes, specific crRNA for detecting Helicobacter pylori cagA genes, vacA genes and ureB genes, ssDNA fluorescent reporters for Helicobacter pylori rapid detection and virulence typing methods, recombinase polymerase amplification RPA reaction reagents for detecting cagA genes, recombinase polymerase amplification RPA reaction reagents for detecting vacA genes, recombinase polymerase amplification RPA reaction reagents for detecting ureB genes, CRISPR-Cas12a reaction reagents for detecting cagA genes, CRISPR-Cas12a reaction reagents for detecting vacA genes, CRISPR-Cas12a reaction reagents for detecting ureB genes and a digital microfluidics platform; The primer pair for detecting the CagA gene is a cagA upstream primer and a cagA downstream primer; The cagA upstream primer is TAACAACCCTAGTTTTTATCTCTACAAAGAAG, and the cagA downstream primer is GCTTAGAGTCTTTTTGAAAATCCTTAATCTCA; The primer pair for detecting the VacA gene is a VacA upstream primer and a VacA downstream primer; The VacA upstream primer is CTTTTAGTGGAAAATCTAACCGGGAATATCAC, and the VacA downstream primer is AAATCTTCCCAGACTAATATCGTTATTGAAAG; The primer pair for detecting the ureB gene is a ureB upstream primer and a ureB downstream primer; The ureB upstream primer is GCTGAAGAATATTCTATGAACTTAGGTTTCTT, and the ureB downstream primer is CTTGCACATCGTATTTGTCTGCAACATCTAAC; The specific cagA-crRNA for detecting the cagA gene, i.e., the cagA-crRNA is: UAAUUUCUACUAAGUGUAGAUGGATCTCTTCTTGACTCAAT or UAAUUUCUACUAAGUGUAGAUTGCAAGAAATTCCATGAAAT; The specific vacA-crRNA for detecting the vacA gene, i.e., the vacA-crRNA, is: UAAUUUCUACUAAGUGUAGAUGCAGGATCAAGCGCGAATTT or UAAUUUCUACUAAGUGUAGAUGTATCCACACCAGCCTTAAA; The specific ureB-crRNA for detecting the ureB gene, i.e., the ureB-crRNA is: UAAUUUCUACUAAGUGUAGAUATCCGCTAAGCTCGCGTCGT or UAAUUUCUACUAAGUGUAGAUAAGCCAATCGCACCGGCTTC; The structure of the ssDNA fluorescent reporter for the method for rapid detection and virulence typing of Helicobacter pylori is FAM-8N-TAMRA, specifically 5′-FAM-TTATTATT-TAMRA-3′; The RPA reaction reagent for detecting the cagA gene includes: 37 μL of RPA reaction buffer, 1.5 μL of deoxyribonucleoside triphosphate mixture, the initial concentration of the deoxyribonucleoside triphosphate mixture is 10 mM, 2 μL of cagA upstream primer, the initial concentration of the cagA upstream primer is 10 μM, 2 μL of cagA downstream primer, the initial concentration of the cagA downstream primer is 10 μM, 2 μL of sample DNA, 3 μL of DEPC-treated water, and 2.5 μL of magnesium acetate, the initial concentration of magnesium acetate is 280 mM. The RPA reaction reagent for detecting the vacA gene includes: 37 μL of RPA reaction buffer, 1.5 μL of deoxyribonucleoside triphosphate mixture, the initial concentration of the deoxyribonucleoside triphosphate is 10 mM, 2 μL of vacA upstream primer, the initial concentration of the vacA upstream primer is 10 μM, 2 μL of vacA downstream primer, the initial concentration of the vacA downstream primer is 10 μM, 2 μL of sample DNA, 3 μL of DEPC-treated water, and 2.5 μL of magnesium acetate, the initial concentration of magnesium acetate is 280 mM. The RPA reaction reagent for detecting the ureB gene includes: 37 μL of RPA reaction buffer, 1.5 μL of deoxyribonucleoside triphosphate mixture, the initial concentration of deoxyribonucleoside triphosphate is 10 mM, 2 μL of ureB upstream primer, the initial concentration of ureB upstream primer is 10 μM, 2 μL of ureB downstream primer, the initial concentration of ureB downstream primer is 10 μM, 2 μL of sample DNA, 3 μL of DEPC-treated water, and 2.5 μL of magnesium acetate solution, the initial concentration of magnesium acetate is 280 mM. The CRISPR-Cas12a reaction reagent for detecting the cagA gene includes 2 μL of RPA amplification product, 1.25 μL of cagA-crRNA, the starting concentration of cagA-crRNA is 1 μM, 2 μL of NEBuffer r2.1, 1 μL of LbCas12a protein, the starting concentration of LbCas12a protein is 1 μM, 1 μL of ssDNA fluorescent reporter, the starting concentration of ssDNA fluorescent reporter is 10 mM, and 12.75 μL of DEPC water; The CRISPR-Cas12a reaction reagent for detecting the vacA gene includes 2 μL of RPA amplification product, 1.25 μL of vacA-crRNA, the starting concentration of vacA-crRNA is 1 μM, 2 μL of NEBuffer r2.1, 1 μL of LbCas12a protein, the starting concentration of LbCas12a protein is 1 μM, 1 μL of ssDNA fluorescent reporter, the starting concentration of ssDNA fluorescent reporter is 10 mM), and 12.75 μL of DEPC water; The CRISPR-Cas12a reaction reagent for detecting the ureB gene includes 2 μL of RPA amplification product, 1.25 μL of ureB-crRNA, the starting concentration of ureB-crRNA is 1 μM, 2 μL of NEBuffer r2.1, 1 μL of LbCas12a protein, the starting concentration of LbCas12a protein is 1 μM, 1 μL of ssDNA fluorescent reporter, the starting concentration of ssDNA fluorescent reporter is 10 mM, and 12.75 μL of DEPC water; The right side of the digital microfluidic platform is provided with a sample loading area (1), a cagA-RPA reagent area (2), a vacA-RPA reagent area (3) and a ureB-RPA reagent area (4); the cagA-RPA reagent area (2) is pre-stored with a recombinase polymerase amplification RPA reaction reagent for detecting the cagA gene, the vacA-RPA reagent area (3) is pre-stored with a recombinase polymerase amplification RPA reaction reagent for detecting the vacA gene, and the ureB-RPA reagent area (4) is pre-stored with a recombinase polymerase amplification RPA reaction reagent for detecting the ureB gene; The left side of the digital microfluidic platform is provided with a negative control loading area (5), a cagA-CRISPR reagent area (6), a vacA-CRISPR reagent area (7) and a ureB-CRISPR reagent area (8); the cagA-CRISPR reagent area (6) is pre-stored with a CRISPR-Cas12a reaction reagent for detecting the cagA gene, the vacA-CRISPR reagent area (7) is pre-stored with a CRISPR-Cas12a reaction reagent for detecting the vacA gene, and the ureB-CRISPR reagent area (8) is pre-stored with a CRISPR-Cas12a reaction reagent for detecting the ureB gene.
2. The Helicobacter pylori rapid detection reagent according to claim 1, characterized in that: The bottom of the digital microfluidic platform is provided with an indium tin oxide glass bottom plate, and the top of the digital microfluidic platform is provided with an indium tin oxide glass top plate. The right side of the indium tin oxide glass top plate is respectively provided with RPA reagent injection holes for adding recombinase polymerase amplification RPA reaction reagents for detecting the cagA gene, the recombinase polymerase amplification RPA reaction reagents for detecting the vacA gene, and the recombinase polymerase amplification RPA reaction reagents for detecting the ureB gene. The right side of the indium tin oxide glass top plate is also provided with a sample injection hole for adding samples; the left side of the glass top plate is respectively provided with CRISPR-Cas12a reagent injection holes for adding CRISPR-Cas12a reaction reagents for detecting the cagA gene, the CRISPR-Cas12a reaction reagents for detecting the vacA gene, and the CRISPR-Cas12a reaction reagents for detecting the ureB gene.
3. A method for detecting Helicobacter pylori using the Helicobacter pylori rapid detection reagent according to claim 1, 2 or 3, characterized in that: It includes the following steps: A. preparing a digital microfluidic platform as claimed in claim 1; B. Adding the nucleic acid sample to be tested to the sample loading area of the digital microfluidics platform (1); C. The detection results can be determined by monitoring the changes in the fluorescence signal through the digital microfluidic platform.
Citation Information
Cited By
Droplet digital isothermal nucleic acid amplification method and device based on digital microfluidics and medium
CN120138112A
